Re: Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer.
Samir S
SS
Taneja
D000069501:Abiraterone Acetate; D000736:Androstenes; D000971:Antineoplastic Combined Chemotherapy Protocols; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant; D043823:Taxoids; D016896:Treatment Outcome
D000736:Androstenes; D043823:Taxoids; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate